IV-361 is an orally active and selective CDK7 inhibitor ( K i ≤50 nM). IV-361 has anti-cancer activity (US20190256531A1) In Vitro IV-361 has less inhibition on CDK2 (K i ≥1000 nM) or PLK1 (K i ≥5000 nM). IV-361 exhibits excellent IL-2 and IL-17 production inhibitory activity (all IC 50 ≤100 nM) in periphery blood mononuclear cell (PBMC). IV-361 exhibits excellent HCT-116 cell growth inhibitory activity (GI 50 ≤100 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo IV-361 (25 mg/kg/day; orally) exhibits 46% or more rate of suppression of tumor volume in female BALB nude mice with HCT-116 . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:CDK7 ≤50 nM (Ki) CDK2 ≥1000 nM (Ki)